Accelerate Diagnostics Inc. (AXDX) Trading 1.2% Higher
Shares of Accelerate Diagnostics Inc. (NASDAQ:AXDX) traded up 1.2% during trading on Wednesday . The stock traded as high as $21.98 and last traded at $21.91, with a volume of 122,936 shares changing hands. The stock had previously closed at $21.64.
Several analysts recently commented on the company. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Monday. BTIG Research upgraded Accelerate Diagnostics from a “neutral” rating to a “buy” rating in a report on Thursday, August 25th. JPMorgan Chase & Co. increased their price target on Accelerate Diagnostics from $17.00 to $25.00 and gave the stock an “overweight” rating in a report on Tuesday, August 9th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $25.00 price target on shares of Accelerate Diagnostics in a report on Monday, May 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $25.33.
The firm’s market cap is $1.13 billion. The stock has a 50-day moving average price of $21.05 and a 200-day moving average price of $15.41.
In related news, Director Jack W. Schuler purchased 88,316 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were acquired at an average cost of $14.69 per share, with a total value of $1,297,362.04. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jack W. Schuler purchased 90,147 shares of the firm’s stock in a transaction on Thursday, June 30th. The stock was bought at an average cost of $13.95 per share, for a total transaction of $1,257,550.65. The disclosure for this purchase can be found here.
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.